Published in J Med Primatol on October 24, 2011
Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature (2002) 21.53
Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature (2003) 13.24
DNA deamination mediates innate immunity to retroviral infection. Cell (2003) 12.10
The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature (2003) 10.76
The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med (2003) 9.22
HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell (2003) 7.42
The survival benefits of AIDS treatment in the United States. J Infect Dis (2006) 7.08
A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J (2004) 5.67
Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J Biol Chem (2003) 5.45
Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J Virol (2004) 5.35
HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries? AIDS (2002) 4.56
The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. J Virol (2003) 4.23
Long-term HIV-1 infection without immunologic progression. AIDS (1994) 3.41
Small-molecule inhibition of HIV-1 Vif. Nat Biotechnol (2008) 2.83
Rapid progression to disease in African sex workers with human immunodeficiency virus type 1 infection. J Infect Dis (1995) 2.28
Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G. J Virol (2004) 2.27
The characterization of non-progressors: long-term HIV-1 infection with stable CD4+ T-cell levels. AIDS (1993) 2.00
Mice deficient in APOBEC2 and APOBEC3. Mol Cell Biol (2005) 1.55
Transcriptional regulation of APOBEC3G, a cytidine deaminase that hypermutates human immunodeficiency virus. J Biol Chem (2004) 1.34
Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group. J Infect Dis (2004) 1.31
Long-term survivors with HIV-1 infection: incubation period and longitudinal patterns of CD4+ lymphocytes. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 1.22
The antiviral factor APOBEC3G improves CTL recognition of cultured HIV-infected T cells. J Exp Med (2009) 1.07
HIV-1 Vif binds to APOBEC3G mRNA and inhibits its translation. Nucleic Acids Res (2009) 1.00
The effect of allogeneic in vitro stimulation and in vivo immunization on memory CD4(+) T-cell APOBEC3G expression and HIV-1 infectivity. Eur J Immunol (2009) 0.93
Recent developments in drug targets and delivery of anti-HIV drugs. Infect Disord Drug Targets (2006) 0.83
Development of a chronically catheterized maternal-fetal macaque model to study in utero mother-to-fetus HIV transmission: a preliminary report. J Med Primatol (1996) 0.77
Long-acting three-drug combination anti-HIV nanoparticles enhance drug exposure in primate plasma and cells within lymph nodes and blood. AIDS (2014) 1.76
Lipid-drug association enhanced HIV-1 protease inhibitor indinavir localization in lymphoid tissues and viral load reduction: a proof of concept study in HIV-2287-infected macaques. J Acquir Immune Defic Syndr (2003) 1.55
Optimization of lipid-indinavir complexes for localization in lymphoid tissues of HIV-infected macaques. J Acquir Immune Defic Syndr (2006) 1.29
The role of MDR1 genetic polymorphisms in interindividual variability in P-glycoprotein expression and function. Curr Drug Metab (2004) 1.26
Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems. J Pharm Sci (2013) 1.16
Novel Gd nanoparticles enhance vascular contrast for high-resolution magnetic resonance imaging. PLoS One (2010) 1.15
In vitro-to-in vivo prediction of P-glycoprotein-based drug interactions at the human and rodent blood-brain barrier. Drug Metab Dispos (2007) 1.11
pH-dependent interactions of indinavir and lipids in nanoparticles and their ability to entrap a solute. J Pharm Sci (2008) 1.09
Multidrug resistance gene G1199A polymorphism alters efflux transport activity of P-glycoprotein. J Pharmacol Exp Ther (2004) 1.05
MDR1 haplotypes significantly minimize intracellular uptake and transcellular P-gp substrate transport in recombinant LLC-PK1 cells. J Pharm Sci (2006) 1.03
Drug delivery trends in clinical trials and translational medicine. J Pharm Sci (2008) 1.02
MDR1 G1199A polymorphism alters permeability of HIV protease inhibitors across P-glycoprotein-expressing epithelial cells. AIDS (2005) 1.02
Novel liquid chromatography-tandem mass spectrometry method for simultaneous detection of anti-HIV drugs Lopinavir, Ritonavir, and Tenofovir in plasma. Antimicrob Agents Chemother (2014) 0.95
A novel MDR1 G1199T variant alters drug resistance and efflux transport activity of P-glycoprotein in recombinant Hek cells. J Pharm Sci (2006) 0.94
Drug delivery trends in clinical trials and translational medicine: evaluation of pharmacokinetic properties in special populations. J Pharm Sci (2011) 0.94
Inhibition of P-glycoprotein activity at the primate blood-brain barrier increases the distribution of nelfinavir into the brain but not into the cerebrospinal fluid. Drug Metab Dispos (2007) 0.94
Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates. AIDS Res Hum Retroviruses (2015) 0.93
Enhanced anti-HIV efficacy of indinavir after inclusion in CD4-targeted lipid nanoparticles. J Acquir Immune Defic Syndr (2012) 0.90
The impact of pharmacologic and genetic knockout of P-glycoprotein on nelfinavir levels in the brain and other tissues in mice. J Pharm Sci (2005) 0.87
pH-responsive artemisinin derivatives and lipid nanoparticle formulations inhibit growth of breast cancer cells in vitro and induce down-regulation of HER family members. PLoS One (2013) 0.86
MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol (2009) 0.85
Enhanced analgesic responses after preferential delivery of morphine and fentanyl to the olfactory epithelium in rats. Anesth Analg (2011) 0.85
Interactions of indocyanine green and lipid in enhancing near-infrared fluorescence properties: the basis for near-infrared imaging in vivo. Biochemistry (2014) 0.83
Recent developments in drug targets and delivery of anti-HIV drugs. Infect Disord Drug Targets (2006) 0.83
Development and characterization of a recombinant Madin-Darby canine kidney cell line that expresses rat multidrug resistance-associated protein 1 (rMRP1). AAPS PharmSci (2004) 0.83
Effects of localized hydrophilic mannitol and hydrophobic nelfinavir administration targeted to olfactory epithelium on brain distribution. AAPS PharmSciTech (2011) 0.82
Cloning and characterization of the rat multidrug resistance-associated protein 1. AAPS PharmSci (2002) 0.81
An RT-PCR-based strategy to estimate full-length CYP2D6 mRNA copy number. Genet Test (2004) 0.80
Development and characterization of transgenic mouse models for conditional gene knockout in the blood-brain and blood-CSF barriers. Transgenic Res (2011) 0.80
Human liver cytochrome P450 2D6 genotype, full-length messenger ribonucleic acid, and activity assessed with a novel cytochrome P450 2D6 substrate. Clin Pharmacol Ther (2004) 0.80
Design and characterization of novel peptide-coated lipid nanoparticles for targeting anti-HIV drug to CD4 expressing cells. AAPS J (2012) 0.80
Effects of Garlic on Cytochromes P450 2C9- and 3A4-Mediated Drug Metabolism in Human Hepatocytes. Sci Pharm (2010) 0.79
Effects of photoactivated 5-aminolevulinic acid hexyl ester on MDR1 over-expressing human uterine sarcoma cells. Toxicol Lett (2008) 0.79
HIV in central nervous system and behavioral development: an HIV-2287 macaque model of AIDS. AIDS (2004) 0.79
Novel cytochrome P450-2D6 promoter sequence variations in hepatitis C positive and negative subjects. Ann Hepatol (2011) 0.78
A novel human multidrug resistance gene MDR1 variant G571A (G191R) modulates cancer drug resistance and efflux transport. J Pharmacol Exp Ther (2008) 0.78
Combining drug and immune therapy: a potential solution to drug resistance and challenges of HIV vaccines? Curr HIV Res (2008) 0.77
Evaluation of atazanavir and darunavir interactions with lipids for developing pH-responsive anti-HIV drug combination nanoparticles. J Pharm Sci (2014) 0.77
Only truncated, not complete cytochrome p450 2D6 RNA transcript and no detectable enzyme activity are expressed in human lymphocytes. Drug Metab Dispos (2003) 0.77
AIDS treatment with novel anti-HIV compounds improved by nanotechnology. AAPS J (2010) 0.77
Variant CYP2C9 alleles and warfarin concentrations in patients receiving low-dose versus average-dose warfarin therapy. Clin Appl Thromb Hemost (2007) 0.76
Two decades of publishing excellence in pharmaceutical biotechnology. J Pharm Sci (2014) 0.75
pH-responsive artemisinin dimer in lipid nanoparticles are effective against human breast cancer in a xenograft model. J Pharm Sci (2015) 0.75
Aerosol-stable peptide-coated liposome nanoparticles: a proof-of-concept study with opioid fentanyl in enhancing analgesic effects and reducing plasma drug exposure. J Pharm Sci (2014) 0.75
Antiretroviral nanoparticles: the future is now: authors' response to editorial comments. AIDS (2015) 0.75
A novel MDR1 GT1292-3TG (Cys431Leu) genetic variation and its effect on P-glycoprotein biologic functions. AAPS J (2010) 0.75
Long-acting combination anti-HIV drug suspension enhances and sustains higher drug levels in lymph node cells than in blood cells and plasma. AIDS (2017) 0.75
Design and characterization of a novel lipid-DNA complex that resists serum-induced destabilization. J Pharm Sci (2003) 0.75
Feasibility of weekly HIV drug delivery to enhance drug localization in lymphoid tissues based on pharmacokinetic models of lipid-associated indinavir. Pharm Res (2006) 0.75
Effects of lipid association on lomustine (CCNU) administered intracerebrally to syngeneic 36B-10 rat brain tumors. Cancer Lett (2006) 0.75